Oncomine Precision Assay(opa)ffpe-50 Genes

What is Oncomine Precision Assay on FFPE Tissue block test?

Oncomine Precision Assay on FFPE Tissue block is a 50 gene panel is a rapid NGS (Genexus) based panel that profiles DNA and RNA across 50 key cancer genes to detect actionable mutations, copy‑number changes, and gene fusions.

Agilus Diagnostics offers fastest reporting in 7 working days while the conventional panel take up to 30 days of reporting. This unique feature allows clinicians to make rapid decisions and enable faster treatment.

Why consider Oncomine Precision Assay on FFPE Tissue block test?

This panel is recommended in below clinical conditions -

• Detects clinically relevant driver and resistance alterations across common targets, informing approved therapies and clinical trial options.
• Consolidates multiple biomarkers into one assay from minimal tissue, reducing repeat biopsies and delivering results quickly to expedite decisions.
• Independent validations report high analytical accuracy, sensitivity, and reproducibility for SNVs/INDELs, with robust fusion detection at low inputs on Genexus workflows.

Who should get this Oncomine Precision Assay on FFPE Tissue block test?

• Patients with advanced or metastatic solid tumors where comprehensive genomic profiling may influence first‑line therapy or options at progression, especially when tissue is limited.
• Tumor types with multiple actionable pathways (e.g., lung, colorectal, cholangiocarcinoma, thyroid, ovarian, breast, prostate, sarcomas) where a focused 50‑gene panel captures key biomarkers efficiently.

More Information about Oncomine Precision Assay on FFPE Tissue block test

Oncomine Precision Assay on FFPE Tissue block is a 50 gene panel is a rapid NGS (Genexus) based panel that profiles DNA and RNA across 50 key cancer genes to detect actionable mutations, copy‑number changes, and gene fusions.

OTHER NAMES: Oncomine Precision Assay (OPA) on Genexus, OPA FFPE 50‑gene panel, Oncomine 50‑gene actionable panel, CGP panel, Comprehensive genomic profiling, Cancer Hotspot 50 gene panel, Caner Gene panel, cancer 50 gene panel.